Evotec SE (EVO) Earnings Call Analysis

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

13/25

Growth 3 Margin 0 Expansion 5 Platform 3 Financial 2

latest quarter score

Earnings Reports

13
Evotec (EVO) Q2 2026: Revenue Guidance Cut by Up to 22% Amid Strategic Partnership Timing Shifts
July 14, 2026
12
EVO (EVO) Q1 2026: Double-Digit D&PD Order Growth Sets Up H2 Recovery Amid Strategic Review
May 06, 2026
18
Evotech (EVO) Q4 2025: Just Biologics Grows 40%, Reshapes Margin Profile for 2026
April 13, 2026
14
EVO (EVO) Q3 2025: Sandoz Deal Unlocks $650M Upside, Shifts Biologics to Asset-Light Model
November 06, 2025
21
Evotec SE (EWTX) H1 2025: 16% Growth in Just – Evotec Biologics Offsets Discovery Segment Softness
August 13, 2025
18
Evotec (EVT) Q1 2025: 10% Growth in Just – Evotec Biologics Offsets 9% Shared R&D Revenue Decline
May 06, 2025
19
Evotec SE (EVO) Q4 2024: 71% Biologics Revenue Surge Drives Strategic Pivot Toward Profitable Growth
April 17, 2025

Browse all companies